Prothena Alzheimers PRX012Prothena states We are excited for initial topline results from our ongoing Phase 1 SAD and MAD clinical trials of PRX012, an anti-amyloid beta antibody. Judging by the stock price which has dropped from $70 to $35 since July might say something about possible results. Shorts have also increased from 3.7 million in July to 6.5 million Oct/31.